Related references
Note: Only part of the references are listed.Potential years of life lost (PYLL) caused by asbestos-related diseases in the world
Rachmania Diandini et al.
AMERICAN JOURNAL OF INDUSTRIAL MEDICINE (2013)
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. L. Ceresoli et al.
BRITISH JOURNAL OF CANCER (2013)
Phase II study of pemetrexed as first-line treatment in elderly (aparts per thousandyen75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Young Hak Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
Radj Gervais et al.
LUNG CANCER (2013)
How ageing processes influence cancer
Joao Pedro de Magalhaes
NATURE REVIEWS CANCER (2013)
Prognosis and prognostic factors of patients with mesothelioma: a population-based study
S. van der Bij et al.
BRITISH JOURNAL OF CANCER (2012)
Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non-Small-Cell Lung Cancer
Cesare Gridelli et al.
CLINICAL LUNG CANCER (2012)
Future Trends of Mesothelioma Mortality in Japan Based on a Risk Function
Tomoya Myojin et al.
INDUSTRIAL HEALTH (2012)
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
Alessandro Marinaccio et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
Valerie W. Rusch et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review
Marije E. Hamaker et al.
LANCET ONCOLOGY (2012)
Impact of Age and Comorbidity on Treatment and Outcomes in Elderly Cancer Patients
Ronald C. Chen et al.
SEMINARS IN RADIATION ONCOLOGY (2012)
Integrating a Geriatric Evaluation in the Clinical Setting
Martine Extermann
SEMINARS IN RADIATION ONCOLOGY (2012)
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors
A. G. Pallis et al.
ANNALS OF ONCOLOGY (2011)
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008
Vanya Delgermaa et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2011)
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2011)
Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool
Antonella Brunello et al.
CANCER TREATMENT REVIEWS (2009)
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
Bertram Price et al.
CRITICAL REVIEWS IN TOXICOLOGY (2009)
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
B. Castagneto et al.
ANNALS OF ONCOLOGY (2008)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. L. Ceresoli et al.
BRITISH JOURNAL OF CANCER (2008)
Projected mesothelioma incidence in men in New South Wales
Mark Clements et al.
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2007)
A user's guide to selecting a comorbidity index for clinical research
Stephen F. Hall
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
GL Ceresoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Survival from rare cancer in adults:: a population-based study
G Gatta et al.
LANCET ONCOLOGY (2006)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
MJ Byrne et al.
ANNALS OF ONCOLOGY (2004)
An electronic application for rapidly calculating Charlson comorbidity score
WH Hall et al.
BMC CANCER (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma
GL Ceresoli et al.
LUNG CANCER (2001)
Share Paper
